H. David Friedland

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

Martín E. Stryjewski, Donald R. Graham, Samuel E. Wilson et al. · Clinical Infectious Diseases · 2008 · 288 citations

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

Eric Rubinstein, Tahaniyat Lalani, G. Ralph Corey et al. · Clinical Infectious Diseases · 2010 · 246 citations · Full text

Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection

G. Ralph Corey, Mark H. Wilcox, George H. Talbot et al. · Clinical Infectious Diseases · 2010 · 236 citations

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Thomas M. File, Donald E. Low, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 196 citations · Full text

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

Thomas M. File, Donald E. Low, Paul B. Eckburg et al. · Clinical Infectious Diseases · 2010 · 185 citations · Full text